drugset / Trial / NCT04501120
Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
Phase 1/2
Recruiting
682 enrolled
Ascentage Pharma Group Inc.
Suzhou Yasheng Pharmaceutical Co., Ltd. · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety, pharmacokinetic profile of Lisaftoclax (APG-2575) single agent and in combination with HHT/AZA in patients with relapsed/refractory AML and related myeloid malignancies.
Timeline
- Start
- 2020-09-28
- Primary completion
- 2028-09
- Completion
- 2029-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | APG-2575 | Small molecule | 200 mg | Oral |
| Subject | APG-2575 | Small molecule | 400 mg | Oral |
| Subject | APG-2575 | Small molecule | 600 mg | Oral |
| Subject | APG-2575 | Small molecule | 800 mg | Oral |
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | Subcutaneous |
| Subject | Homoharringtonine | Small molecule | 1 mg | Intravenous |
| Subject | Homoharringtonine | Small molecule | 2 mg/m2 | Intravenous |
| Subject | Olverembatinib | Small molecule | — | Oral |